Milk Thistle (Silybum marianum): A Comprehensive Reference
1. Identity and Botanical Overview
Botanical and Chemical Names
The botanical name for milk thistle is Silybum marianum (L.) Gaertn. It is a medicinal plant from the Asteraceae family. The species has acquired numerous common names throughout its history of use: these include holy thistle, Marian thistle, Mary thistle, Our Lady's thistle, St. Mary thistle, wild artichoke, Mariendistel (German), and Chardon-Marie (French).
Milk thistle is an ancient plant, tracing back to North Africa and the Mediterranean. It earned its botanical name, Silybum marianum, from the white marbling on its leaves. Tradition has it that the milky-white veins of the leaves originated from the milk of the Virgin Mary, which once fell upon a plant of the thistle, hence the names St. Mary's thistle and Our Lady's thistle, and also the species epithets marianus and marianum.
Natural Source and Distribution
The plant is indigenous to Europe but can also be found in the United States and South America. Originally native to the Mediterranean region, it now grows in temperate climates across the world. It often thrives in dry, rocky soil and is known for being resilient and fast-growing.
Medicinal Part
The seed-like fruits (achenes) of milk thistle are the medicinal parts of the plant. Traditionally, the leaves have been used in salads, and the fruit of the flower has been roasted as a coffee substitute.
Common Preparations and Dosage Forms
Because of the lipophilic nature of its active constituents, milk thistle is usually administered as an extract in capsule or tablet form rather than as an herbal tea. Milk thistle is marketed as capsules or tablets containing ethanol-extracted silymarin in amounts of 250 to 750 mg and is purported to be beneficial for liver disease, including alcoholic and viral liver disease. The daily dosage varies but it is typically taken 2 to 3 times daily.
Milk thistle fruit and seeds are also used to make tea or dietary supplements, such as tablets or capsules. The dose of milk thistle is usually based on the amount of silymarin contained in the product; silymarin is the substance in milk thistle that is thought to have effects in the body. Special formulations of silymarin and/or the silybins have been developed to enhance their bioavailability by conjugation with phosphatidylcholine. Intravenous preparations of purified silybinin are approved in Europe for therapy of Amanita phalloides mushroom poisoning.
2. Traditional and Historical Use
Ancient Greece and Rome
Therapeutic properties of milk thistle were first documented by the Greek physician and botanist Dioscorides (in 40–90 AD). Dioscorides, the Roman army doctor, used the seeds of milk thistle as a remedy for infants and those bitten by serpents. It is said that the Roman naturalist Pliny the Elder (AD 23–79) wrote about the plant's juice and its virtues of "carrying of bile," which in his time referred to a general description of any internal fluid.
Throughout history, milk thistle has been employed to treat a variety of ailments. Ancient Romans and Greeks often turned to this herb as a remedy for liver-related concerns, believing it could cleanse the blood and restore the organ. During this time, milk thistle also became a common treatment for snake bites, mushroom poisoning, and gallbladder ailments.
Middle Ages and European Herbal Traditions
During the Middle Ages, herbalists and healers expanded its use, applying it to treat conditions such as jaundice, liver congestion, and insect stings. By the Middle Ages, milk thistle had spread throughout Europe where it became a staple in monastery gardens. Herbalists prescribed it for melancholy (depression) and liver congestion.
In the 18th century, milk thistle was also used for liver conditions. In Middle Europe, and especially in Prussia, the plant was cultured already in the 17th and 18th century. In the mid-19th century, milk thistle was used for hepatic diseases, as well as for flatulence, constipation, and haemorrhoids. When silymarin was discovered in fruit extracts and its protective effect on the liver was confirmed in scientific trials, the role of milk thistle in therapy was reinstated.
Traditional Iranian Medicine
In the book "Al-Hashaish Dioscorides," which is one of the sources of traditional medicine, this plant is introduced with the name "Harshfbari," and its properties and other names are similar to other sources of traditional Iranian medicine.
American Eclectic and Basque Traditions
American Eclectics used a seed tincture for lack of menstruation, bleeding, dysuria (difficulties with urination), gallstones, hyperaemia, haematuria, liver diseases, chronic vomiting, and nephrotic syndrome. The Basques used a seed decoction as an anti-inflammatory, anti-cancer, purgative, diuretic agent, and for improvement of digestion, stopping bleeding, and blood pressure reduction.
Milk thistle is traditionally used in Europe as a vegetable in salads, and the seeds are used as a galactagogue for breastfeeding mothers.
3. Key Constituents and Active Compounds
Silymarin: The Primary Active Complex
The active constituent of milk thistle is silymarin, which is a complex mixture of flavonoids and flavonoid derivatives, the flavonolignans. The major constituents of silymarin are the three diastereomeric pairs: silybins A and B (also called silibinin), isosilybins A and B, silychristin, isosilychristin, and silydianin. Silymarin's primary constituents are the flavonolignan isomers silybins A and B, isosilybins A and B, silychristin (also known as silichristin), silydianin (also known as silidianin), and their flavonoid precursor, taxifolin.
Silymarin is the major constituent of milk thistle extract and is a mixture of some flavonolignans such as silybin, which is the most active component of silymarin. Most supplements are standardized according to their silybin content.
Other Constituents
This plant contains at least seven flavolignands and the flavonoid taxifolin. In addition to silymarin, milk thistle seeds contain small amounts of naturally occurring compounds such as vitamin E, fatty acids, and polyphenols. Research studies conducted in the laboratory have investigated the properties of silymarin or its isomer silybin using cell lines and animal models. Other substances in milk thistle have not been extensively studied.
4. Mechanisms of Action
Hepatoprotective Mechanisms
Evidence exists that milk thistle may be hepatoprotective through a number of mechanisms: antioxidant activity, toxin blockade at the membrane level, enhanced protein synthesis, antifibrotic activity, and possible anti-inflammatory or immunomodulating effects.
Milk thistle exhibits its hepatoprotective properties by three major mechanisms: acting as an antioxidant, an anti-inflammatory, and an antifibrotic substance. The hepatoprotective and antioxidant activity of silymarin is caused by its ability to inhibit the free radicals that are produced from the metabolism of toxic substances such as ethanol, acetaminophen, and carbon tetrachloride. The generation of free radicals is known to damage cellular membranes and cause lipoperoxidation. Silymarin enhances hepatic glutathione and may contribute to the antioxidant defense of the liver.
Silymarin is the most used natural compound for the treatment of hepatic diseases worldwide due to its antioxidant, anti-inflammatory, and anti-fibrotic activities. Silymarin functions by stabilizing biological membranes and increasing protein synthesis.
Anti-inflammatory Pathways
The anti-inflammatory properties of milk thistle are attributable to its ability to regulate cytokines responsible for inducing inflammation. Milk thistle has been shown to down-regulate and inhibit the expression of COX-2, a key mediator of inflammatory pathways. Silymarin also inhibits the transduction cascade controlled by NF-κB.
Mechanistic studies have clarified that silymarin's major bioactive constituents, like silibinin, silydianin, and silychristin, interact with redox-sensitive transcriptional pathways such as Nrf2/ARE and NF-κB, while also influencing metabolic regulators like AMPK and SIRT1. These mechanisms collectively work for their antioxidant, anti-inflammatory, and antifibrotic actions.
Molecular Signaling Interactions
The therapeutic activity of silymarin manifests through its interaction with various receptors and growth factors, including mitogen-activated protein kinases (MAPKs), mammalian target of rapamycin (mTOR), β-catenin, AKT, apoptotic proteins, and inflammatory cytokine gene expression.
Anti-Viral and Immunomodulatory Actions
Silymarin also inhibits hepatitis C virus (HCV) infection and displays antioxidant, anti-inflammatory, and immunomodulatory actions that contribute to its hepatoprotective effects. Activities demonstrated in laboratory settings include inhibition of: HCV cell culture infection, NS5B polymerase activity, TNF-alpha-induced NF-κB transcription, virus-induced oxidative stress, and T-cell proliferation.
Antifibrotic Effects
Through its potent antioxidant, anti-inflammatory, and hepatoprotective properties, silymarin has shown efficacy in improving liver function, reducing oxidative stress, and mitigating liver inflammation. Clinical studies suggest that silymarin can effectively enhance endogenous antioxidant defenses, stabilize cell membranes, and promote hepatic regeneration, thereby contributing to the overall health and functionality of the liver.
Metabolic Mechanisms (Diabetes)
A substance from milk thistle has been shown to possess peroxisome proliferator-activated receptor γ (PPARγ) agonist properties. PPARγ is the molecular target of thiazolidinediones, which are used clinically as insulin sensitizers to lower blood glucose levels in type 2 diabetes patients. Oxidative stress is known as an important factor in impairing insulin homeostasis, which leads to insulin resistance and blood glucose impairment, which ends at type 2 diabetes mellitus.
5. Scientific Evidence by Health Area
5.1 Liver Disease (General)
Results from clinical trials of milk thistle for liver diseases, such as alcohol-related liver disease, hepatitis B and C, non-alcoholic fatty liver disease, and liver problems caused by cancer chemotherapy, low oxygen levels, or toxins have been conflicting or too limited to allow conclusions to be reached. There isn't enough high-quality evidence to allow definite conclusions to be reached about the effects of milk thistle on health conditions in people.
5.2 Alcoholic Liver Disease and Cirrhosis
Thirteen randomized clinical trials assessed milk thistle in 915 patients with alcoholic and/or hepatitis B or C liver diseases. Based on high-quality trials, milk thistle does not seem to significantly influence the course of patients with alcoholic and/or hepatitis B or C liver diseases. The methodological quality of these trials was generally low: only 23% reported adequate allocation concealment and only 46% were considered double blind.
A Cochrane systematic review could not demonstrate significant effects of milk thistle on mortality or complications of liver diseases in patients with alcoholic and/or hepatitis B or C liver diseases combining all trials or high-quality trials. Low-quality trials suggested beneficial effects. High-quality randomised clinical trials on milk thistle versus placebo are needed.
In alcoholic liver disease, comparing with placebo, aspartate aminotransferase was reduced in the silymarin-treated groups (p = 0.01), while alkaline phosphatase was not. Based on the available clinical evidence it can be concluded — concerning possible risks/probable benefits — that it is reasonable to employ silymarin as a supportive element in the therapy of Amanita phalloides poisoning but also in (alcoholic and grade Child 'A') liver cirrhosis.
5.3 Hepatitis C Virus (HCV)
A multicenter, double-blind, placebo-controlled trial was conducted at 4 medical centers in the United States. Participants included 154 persons with chronic HCV infection and serum alanine aminotransferase (ALT) levels of 65 U/L or greater who were previously unsuccessfully treated with interferon-based therapy. Current research suggests that milk thistle is no better than placebo as a treatment for hepatitis C. A 2017 systematic review and meta-analysis of a total of 23 trials evaluated the effect of silymarin on the serum levels of ALT, AST, and gamma glutamyl transpeptidase in patients with liver diseases. The authors concluded that silymarin minimally reduced the serum levels of ALT and AST; however, the results were without clinical relevance. They also noted the need to conduct studies with more appropriate methodological designs.
5.4 Liver Enzyme Levels (Systematic Review)
Of 1,707 initially identified articles, 29 RCTs met the inclusion criteria of a 2023 systematic review following PRISMA 2020 guidelines, encompassing 3,846 participants with diverse underlying conditions. Silymarin offers protective effects on the liver and shows promise in improving liver function and histological outcomes in various chronic liver conditions. Despite the promising results, further research is needed to fully elucidate the optimal dosing regimens, long-term safety, and potential drug interactions of silymarin.
5.5 Non-Alcoholic Fatty Liver Disease (NAFLD / MASLD)
Research has indicated that milk thistle has the potential to reduce biochemical changes seen in patients with NAFLD, and multiple pharmacological studies have demonstrated why many consider the plant to be a hepatoprotective substance. Controlled trials of silymarin in chronic hepatitis C and non-alcoholic fatty liver disease found little or no evidence of benefit in ameliorating disease activity or in slowing disease progression.
Patients treated with 600 mg/d of silymarin for 12 months demonstrated lower fasting insulin levels. A separate clinical trial evaluated silymarin's effectiveness compared to metformin and pioglitazone in NAFLD patients.
5.6 Amanita Phalloides (Mushroom) Poisoning
A retrospective review of the treatment for Amanita phalloides poisoning suggests that silymarin has been shown to be an effective drug in the treatment of this mushroom poisoning. In Europe, silybin is administered intravenously as the only effective antidote for Amanita phalloides poisoning. The mechanism by which silybin A and silybin B protect the liver from the effects of RNA polymerase II inhibition by α-amanitin appears to converge on the inhibition of toxin uptake into hepatocytes by silibinin.
No prospective controlled trials of intravenous silybinin have been published. Evidence is derived from retrospective case series and observational data. Healthcare workers should be aware that currently, there is no firm clinical evidence to recommend silybin or silymarin in the clinical setting for most indications outside of intravenous use in amatoxin poisoning.
5.7 Radiation-Induced Skin Toxicity in Cancer
In a non-randomized observational trial of 101 women with breast cancer who had undergone breast-conserving surgery followed by radiation therapy, a silymarin-based cream (Leviaderm) was tested in 51 women compared with panthenol-containing cream as the standard of care. The median time to toxicity was prolonged significantly with the silymarin-based cream (45 vs. 29 days, P < .0001). This evidence is preliminary; the trial was non-randomized and observational.
5.8 Type 2 Diabetes Mellitus
Results from a small number of studies in people show that milk thistle extracts may help to control blood sugar in people with type 2 diabetes. Most of this research was done in Middle Eastern countries, and it is unclear whether the same results would be seen in other parts of the world.
A 2021 systematic review and meta-analysis showed that silymarin supplementation can decrease fasting blood sugar (FBS), hemoglobin A1C (HbA1c), and low-density lipoprotein cholesterol (LDL-C), but it has no effect on total cholesterol (TC) or total triglyceride (TG). This systematic review included seven clinical trials assessing the efficacy of silymarin on glycemic indices and serum lipid profiles. A meta-analysis was conducted on 7 studies and 350 patients.
The investigation suggests that silymarin administration has beneficial effects on glycemic indices such as FBS and HbA1c, but the results for lipid profile ingredients (TC, TG) are imprecise and uncertain, and overall the available evidence is insufficient to draw definitive conclusions.
A 4-month, placebo-controlled study among people with type 2 diabetes on conventional therapy (metformin and glibenclamide) showed that 200 mg of milk thistle extract three times daily (600 mg/day total) decreased blood sugar, HbA1c, and LDL cholesterol levels compared to placebo. A 12-month study in Italy found that silymarin extract providing 200 mg of silymarin three times daily (600 mg/day) reduced insulin resistance in people with coexisting diabetes and alcoholic cirrhosis. However, this study was not placebo-controlled.
5.9 Oncology (Preclinical and Early Clinical)
Milk thistle and silymarin have been used as complementary treatments for cancers such as skin, prostate, and colorectal cancers, as well as hepatoprotective agents. Silymarin exerts a chemopreventive effect on reactivating cell death pathways by modulation of antiapoptotic proteins and synergizing with agonists of death domain receptors. Based on the results of patents and laboratory research, silymarin could be beneficial to oncology patients, especially for the treatment of the side effects of anticancer chemotherapeutics.
In a trial of biologic therapy for patients with chronic hepatitis, patients taking silymarin had less symptoms and a better quality of life compared to patients not taking silymarin. Silymarin has been found to help with iron chelation therapy, which removes extra iron in the blood of patients who have had many blood transfusions.
The majority of anti-cancer evidence for milk thistle remains at the in-vitro and animal level. Milk thistle has been studied for the treatment and prevention of cancer, but clinical studies are largely heterogeneous and contradictory.
5.10 Neuroprotection (Alzheimer's, Parkinson's)
Studies have shown other therapeutic effects of silymarin such as anticancer, anti-Alzheimer, anti-Parkinson, and anti-diabetic effects, so interest in researching this supplement remains high. Other studies have shown potential therapeutic effects such as anticancer, anti-diabetic, anti-Alzheimer, and anti-Parkinson effects, so interest in researching this supplement remains high. However, as of current evidence, these claims remain largely preliminary and based on laboratory or animal research, without robust human clinical trial data.
5.11 Kidney Protection
Silymarin, the extract of milk thistle, and its major active flavonolignan silybin are common products widely used in the phytotherapy of liver diseases. They also have promising effects in protecting the pancreas, kidney, myocardium, and the central nervous system. However, inconsistent results are noted in the different clinical studies due to the low bioavailability of silymarin.
6. Body Systems and Health Areas Associated With Milk Thistle
- Hepatic (liver) system: The primary and most extensively researched area; includes alcoholic liver disease, viral hepatitis, NAFLD/MASLD, cirrhosis, and toxic liver injury.
- Biliary (gallbladder) system: Traditional use for gallbladder disorders and bile secretion; referenced in ancient texts.
- Metabolic/endocrine system: Glycemic control and insulin sensitivity in type 2 diabetes mellitus.
- Cardiovascular/lipid system: Emerging evidence for LDL reduction; effects on total cholesterol and triglycerides remain uncertain.
- Neurological system: Preliminary laboratory evidence for neuroprotection in Alzheimer's and Parkinson's disease models.
- Oncological applications: Chemopreventive and supportive roles studied in skin, prostate, and colorectal cancers; evidence remains largely preclinical.
- Dermatological: Topical silymarin-based cream studied for radiation-induced skin reactions.
- Renal system: Preliminary evidence for kidney protection.
7. Dosage Forms and Dosages Reported in Studies
Oral Forms
Milk thistle is marketed as capsules or tablets containing ethanol-extracted silymarin in amounts of 250 to 750 mg. In an oral form standardized to contain 70 to 80 percent silymarin, milk thistle appears to be safe for up to 41 months of use.
Dosages Used in Clinical Studies
- The landmark Ferenci et al. trial in liver cirrhosis used 140 mg of silymarin three times daily. After following participants for four years, the survival rate was 58% in the silymarin group compared with 39% in the placebo group (p=0.036). Patients with alcoholic cirrhosis responded more strongly than those with other forms of the disease.
- A 4-month, placebo-controlled study in type 2 diabetes used 200 mg of milk thistle extract three times daily (600 mg/day total).
- A 12-month Italian study used silymarin extract providing 200 mg of silymarin three times daily (600 mg/day) in persons with diabetes and alcoholic cirrhosis.
- Patients in one NAFLD trial were treated with 600 mg/d of silymarin for 12 months.
- Silymarin has been shown to be well tolerated even at a high dose of 700 mg three times a day for 24 weeks.
- Asymptomatic liver toxicity in clinical trials performed on cancer patients has been reported at extremely high doses of silybin, between 10 to 20 g/d.
Intravenous Preparations
In Europe, silybin is administered intravenously as the only effective antidote for Amanita phalloides poisoning. Intravenous preparations of purified silybinin are approved in Europe for therapy of Amanita phalloides mushroom poisoning. No prospective controlled trials of intravenous silybinin have been published.
8. Bioavailability and Formulation Challenges
Silymarin has relatively poor oral bioavailability due to its low water solubility and limited intestinal absorption. The clinical outcomes of the hepatoprotective effects are varied for silymarin, mainly caused by its low bioavailability.
Several strategies have been developed to improve absorption. Phospholipid complexes (phytosomes), containing phospholipids such as phosphatidylcholine, may increase absorption of silymarin and its silybin constituent. Studies in both rats and humans comparing phospholipid-complexed preparations with plain milk thistle extract demonstrated improved absorption, though these studies were conducted when extracts were taken without food — the difference may be smaller when taken with a meal.
One such complex, IdB 1016 (Silybin Phytosome), is a complex of silybin and phosphatidylcholine, which in animal models shows greater oral bioavailability and therefore greater pharmacological activity compared with pure silybin and silymarin. Plasma silybin levels were determined after administration of single oral doses of IdB 1016 and silymarin (equivalent to 360 mg silybin) to 9 healthy volunteers. Although absorption was rapid with both preparations, the bioavailability of IdB 1016 was much greater than that of silymarin, as indicated by higher plasma silybin levels at all sampling times. Regardless of the preparation used, the terminal half-life was relatively short (generally less than 4 hours).
Advances in pharmacokinetic profiling have highlighted the extensive first-pass metabolism and low oral bioavailability of this compound, prompting the development of novel formulation strategies, including nanoemulsions, liposomes, phospholipid complexes, and polymeric nanoparticles.
In a randomized, double-blinded, crossover study, 16 healthy participants received a single dose of either a micellar formulation (LipoMicel Milk Thistle) or a standard formulation at a total daily dose of 130 mg silymarin. Blood concentrations were measured over 24 hours, and key pharmacokinetic parameters — maximum plasma concentration (C_max), time to reach maximum concentration (T_max), and area under the curve (AUC) — were calculated.
Commercial preparations do not always contain the recommended concentrations of silymarin, failing to provide the expected therapeutic effect. While the poor quality of raw material may explain the low concentrations of silymarin, its deliberate removal is suspected to be an adulteration.
9. Safety Considerations and Drug Interactions
General Tolerability
Oral silymarin has few if any adverse side effects and is well tolerated even in high daily doses. Despite its widespread use in patients with and without liver disease, milk thistle has not been implicated in causing serum enzyme elevations or clinically apparent acute liver injury.
Silymarin is safe in humans at therapeutic doses and is well tolerated even at a high dose of 700 mg three times a day for 24 weeks. Some gastrointestinal discomforts occurred, like nausea and diarrhea.
It has no major toxicity in animals. Silybin, silydianin, and silychristin were not cytotoxic and genotoxic at a concentration of 100 μM.
Reported Side Effects
Available evidence from clinical trials in people with liver diseases suggests that milk thistle is generally well-tolerated. Side effects can include a laxative effect, nausea, diarrhea, abdominal bloating and pain, and occasional allergic reactions.
Clinical studies are largely heterogeneous and contradictory. Aside from mild gastrointestinal distress and allergic reactions, side effects are rare, and serious toxicity has rarely been reported.
High-Dose Hepatotoxicity Signal
Asymptomatic liver toxicity in clinical trials performed on cancer patients has been reported; researchers observed an increase in ALT and bilirubin levels. However, this observation was at extremely high doses of silybin (between 10 to 20 g/d).
Allergy Risk
Persons with hypersensitivity to Asteraceae/Compositae plants, chrysanthemums, daisies, or marigolds may have cross-reactive allergic sensitivity to milk thistle.
Potential Hormonal Considerations
Caution is noted for persons with breast cancer, endometriosis, hormone-sensitive conditions, ovarian cancer, uterine cancer, or uterine fibroids.
Pregnancy and Lactation
One clinical trial showed silymarin is safe in pregnancy, and there were no anomalies. Nonetheless, caution should be exercised during pregnancy, and more studies are needed especially in humans. There is no information available about the use of milk thistle during lactation.
Cytochrome P450 Enzyme Interactions
There is no definitive way to monitor blood levels of milk thistle or its compounds, and little data is available on the therapeutic index of the supplement. However, silymarin has been shown to decrease the activity of cytochrome P-450 enzymes and UDP-glucuronosyltransferase (UGT) enzymes, prompting healthcare providers to caution patients against co-administration of milk thistle and specific pharmaceutical agents.
While silymarin has effects on cytochrome P450 enzymes and hepatic transporters in vitro, there is little evidence that it causes clinically significant herb-drug interactions. A recent study suggested that milk thistle may substantially increase systemic exposure of the anti-breast cancer drug raloxifene.
Silymarin has low drug interactions, and it does not have major effects on cytochromes P-450 at standard doses. Some studies demonstrated that the use of silymarin must be with caution when co-administered with narrow therapeutic window drugs.
Efflux Transporter Interactions
The major efflux transporters of silybin are multidrug resistance-associated protein (MRP2) and breast cancer resistance protein (BCRP), based on results from the transporter-overexpressing cell lines and MRP2-deficient rats. Studies have shown that drugs inhibiting BCRP and MRP2, such as piperine or tangeretin, may lead to increased bioavailability of silybin.
Additive Hypoglycemia Risk
A mild blood sugar-lowering effect of milk thistle is clinically relevant when taken alongside antidiabetic medications.
Quality and Standardization Concerns
The largest producer of milk thistle is Madaus (Germany), which makes an extract of concentrated silymarin. However, numerous other extracts exist, and more information is needed on comparability of formulations, standardization, and bioavailability for studies of mechanisms of action and clinical trials. The amount of each chemical in a specific milk thistle product may vary. Different amounts of silymarin or silybin may change the effects of milk thistle on the body.
10. Summary of Evidence Strength
The following characterizes the overall quality of human clinical evidence for milk thistle across its major investigated indications:
- Amanita phalloides poisoning (IV silybin): Strongest clinical support for the intravenous formulation, approved in Europe; evidence from retrospective case series and open-label studies rather than randomized controlled trials.
- Liver enzyme reduction (ALT/AST): Statistically significant reductions have been shown in systematic reviews, but clinical relevance is considered modest and results are mixed across studies.
- Cirrhosis (alcoholic): Some controlled trials show benefit; one landmark trial showed improved 4-year survival at 140 mg three times daily, but results are not consistent across all high-quality studies.
- Hepatitis C: High-quality evidence (including a JAMA multicenter RCT) shows no significant benefit over placebo.
- NAFLD/MASLD: Promising biochemical signals; long-term, large-scale RCT evidence is lacking.
- Type 2 diabetes (adjunct): Small, mostly Middle Eastern RCTs and meta-analyses suggest modest glycemic improvements; evidence is preliminary.
- Cancer, neuroprotection, kidney: Predominantly in vitro and animal data; clinical evidence is insufficient.
Healthcare workers, including physicians, nurse practitioners, nursing staff, and pharmacists, should be aware that currently, there is no firm clinical evidence to recommend silybin or silymarin in the clinical setting.
References
Go back